Prasad Adusumilli
Deputy Chief and Attending, Thoracic Service · New York Presbyterian Hospital
Credentials: · · · · · · ·
History
PresentThoracic Service · New York Presbyterian Hospital
- Present
Department of Surgery · New York Presbyterian Hospital
- Present
Mesothelioma Program · New York Presbyterian Hospital
- 2009–2010
2008–2009- 2001–2008
Southampton University Hospitals
- 1985–1989
Research
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Journal of Clinical Investigation · 2016 · Last of 8 authors · 913 citations
Journal of Thoracic Oncology · 2015 · 593 citations
Cancer Discovery · 2021 · First of 30 authors · Corresponding · 515 citations
- DJ
119 papers
118 papers
- WT
76 papers
69 papers
- MB
61 papers · 12 as a fellow
- JH
58 papers
56 papers
- DM
53 papers
Grants
- 2026–2030
Intraperitoneal CAR T-Cell Therapy for Peritoneal Mesothelioma
Food and Drug Administration · R01
Contact PI · $650K · Sloan-Kettering Inst Can Research
- 2024–2029
Tuning KITv CAR T Cells for the Solid Tumor Environment
National Cancer Institute · R01
Contact PI · $3.2M · Sloan-Kettering Inst Can Research
- 2024–2029
CD28-KITv CAR T Cells with PD-1 Dominant Negative Receptor
National Cancer Institute · UH3
Contact PI · $3M · Sloan-Kettering Inst Can Research
- 2024–2026
CD28-KITv CAR T Cells with PD-1 Dominant Negative Receptor
National Cancer Institute · UG3
Contact PI · $3.1M · Sloan-Kettering Inst Can Research
Clinical trials
- 2023–2027
A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma
Principal investigator · Active not recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
- 2012–2016
Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy
Principal investigator · Completed
Memorial Sloan Kettering Cancer Center
- 2011–2024
Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)
Principal investigator · Completed
Memorial Sloan Kettering Cancer Center